# Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment

> **NCT02966340** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 70 (actual)

## Conditions studied

- Alcoholism

## Interventions

- **DRUG:** Prazosin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02966340
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-01
- **Primary completion:** 2018-03-12
- **Final completion:** 2018-03-12
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2019-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02966340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02966340, "Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02966340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*